Navigation Links
p90RSK: A new therapeutic target for liver fibrosis?
Date:5/13/2009

Cirrhosis is a world wide, bad prognosis liver disease and characterized by excessive collagen deposition and liver function damage. In our previous work, p90RSK is observed significantly up-regulated in association with elevated collagen type I levels in rat liver fibrosis. But detail mechanism of this phenomenon is still unknown.

Now, there has a research article to be published on May 7, 2009 in the World Journal of Gastroenterology addresses this question. The research team led by Professor Zhu from Department of Gastroenterology, Jinling Hospital observed the mechanism between p90RSK and collagen type I in vivo and in vitro.

In fibrotic liver tissue, p90RSK was over-expressed and located in activated HSC, which had a significant positive correlation with collagen type I levels. In HSC-T6 cells transfected with RNAi targeted to p90RSK, the expression of collagen type I was down regulated according with that of p90RSK. However, collagen type I promoter activity was not alternated with up-regulation or down-regulation of p90RSK expression. Otherwise, p90RSK RNAi inhibited the proliferation of HSC significantly. These results indicate that P90RSK was a critical element in activation of HSC, which is primarily responsible for excessive collagen expression via the initiation of HSC proliferation during liver fibrosis.

Lacking of the knowledge about pathological proceeding of liver fibrosis results in the lack of effective method to prevent and treat liver fibrosis. These results prefer a new view of p90RSK on liver fibrosis, and thus may provide a new therapeutic target to liver fibrosis.


'/>"/>

Contact: Lin Tian
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... ... September 23, 2017 , ... ... to fighting obesity of Robert Kushner, director of Chicago’s Center for Lifestyle Medicine ... promoting healthier habits, the article notes that the center routinely recommends weight loss ...
(Date:9/22/2017)... PA (PRWEB) , ... September 22, 2017 , ... ... soon as possible, and they often saves lives. However, if one isn’t accessible ... to widen the availability of defibrillation, I came up with this idea," said ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, ... Educational Leadership and Administration at St. Thomas University in Miami, Florida, was selected ...
(Date:9/22/2017)... ... 22, 2017 , ... First Choice Emergency Room , ... year anniversary of its Houston-Fallbrook facility. , “We are honored to celebrate ... of First Choice Emergency Room Houston-Fallbrook. “It has been a pleasure serving the ...
(Date:9/22/2017)... ... 22, 2017 , ... The freshly released app Smart Mart ... Smart Mart, customers can now order vegetable, fruit, snacks, dairy, or any eatables. ... clothing at discounted prices. Apart from this, Smart Mart has emphasized upon their ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... 7, 2017  Eli Lilly and Company (NYSE: ... streamline operations to more efficiently focus resources on ... structure. Global workforce reductions, including those from a ... impact approximately 3,500 positions. With ... savings of approximately $500 million that will begin ...
Breaking Medicine Technology: